Klein, Kevin http://orcid.org/0000-0002-8250-2375
Gencoglu, Mümün
Heisterberg, Jens
Acha, Virginia
Stolk, Pieter
Funding for this research was provided by:
IFPMA
Article History
Accepted: 14 November 2022
First Online: 6 December 2022
Declarations
:
: The work of KK and PS on this project was funded by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). KK and PS are employed by Exon Consultancy in the Netherlands (ExternalRef removed). MG is employed by IFPMA. JH is employed by NN. VA is employed by MSD.
: KK and PS have no conflicts of interest that are directly relevant to the content of this article. MG declares that he has no conflicts of interest (besides being employed by the not-for-profit organisation IFPMA). VA and JH are employed by pharmaceutical companies, but declare that they have no conflict of interest directly related to the article’s content. IFPMA represents research-based pharmaceutical companies and associations around the world. Some IFPMA members develop, manufacture and market biosimilars. IFPMA supports science-based regulatory frameworks for biosimilars to ensure patients’ safety.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.